16.04.2024 • News

OQ Chemicals Completes US Propionaldehyde Expansion

As part of its strategy to expand the company's application portfolio, Germany-based OQ Chemicals has mechanically completed the expansion of its US plant in Bay City, Texas, for the production of high-purity propionaldehyde.

The project, OQ Chemicals said, will support the operation of Röhm’s new world-scale methyl methacrylate (MMA) plant, which is integrated into the Bay City site.

“This accomplishment reflects the dedication and excellent collaboration of our OQ Chemicals’ team, various partners, contractors, and stakeholders who were all instrumental in reaching this critical milestone,” commented OQ Chemicals project director, Markus Heuwes.

Röhm and OQ Chemicals initiated the joint project in October 2022. The new plant is the first to employ Röhm’s proprietary LiMA technology for the production of MMA, a crucial precursor for applications like coatings, adhesives, medical products, and road markings. Simultaneously, OQ Chemicals began constructing infrastructure and services vital for Röhm’s plant operation.

“Achieving mechanical completion underscores OQ Chemicals’ commitment to delivering projects on time and to the highest quality standards. As we move forward, our focus remains on the final phases of the project, including commissioning, testing, and handover. We are committed to ensuring a seamless transition to operational readiness, so that our partner can realize the full potential of their investment,” said Kyle Hendrix, OQ Chemicals president USA.

© XXLPhoto/Shutterstock
© XXLPhoto/Shutterstock

Company

Logo:

Oxea

Rheinpromenade 4a
40789 Monheim am Rhein
Germany

Company contact







Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.